Andere talen TiumBio Co., Ltd.

Aandelen

A321550

KR7321550006

slotkoers Korea S.E. Andere beurzen 00:00:00 14-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6.510 ^KRW	-4,96%		-9,71%	-33,37%

01/06	Tiumbio Co. Presenteert Fase 1B tussentijdse resultaten voor Tu2218 in combinatie met pembrolizumab op de Asco 2024 Annual Meeting	CI
08/05	TiumBio Co. Kondigt positieve resultaten aan van Fase 2a klinische studie met Merigolix bij patiënten met matige tot ernstige endometriosegerelateerde pijn	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Tiumbio Co., Ltd. Presents Phase 1B Interim Results for Tu2218 in Combination with Pembrolizumab At Asco 2024 Annual Meeting	01/06
TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain	08/05
Tiumbio Co., Ltd. Submits CTA for Phase 1B Clinical Trial of TU7710, A Long-Acting Recombinant Activated Factor VII, in Hemophilia A or B Patients	26/03
TiumBio Co., Ltd. Announces to Initiate Phase 2 Trial of TU2218 for Cancer	11/03
TiumBio Co., Ltd. announced that it has received KRW 19.9999947 billion in funding from SK Chemicals Co.,Ltd	28/12
TiumBio Co., Ltd. announced that it expects to receive funding from SK Chemicals Co.,Ltd	20/12
TiumBio Co., Ltd. announced that it has received KRW 18.5 billion in funding from a group of investors	23-10-23
TiumBio Co., Ltd.(KOSDAQ:A321550) dropped from S&P Global BMI Index	18-09-23
TiumBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	21-03-23
Hansoh Pharmaceutical Group Company Limited Announces Licensing Agreement with Tiumbio Co., Ltd	08-08-22
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates	21-10-21
Protium Science announced that it has received KRW 6 billion in funding from TiumBio Co., Ltd.	27-09-21
Protium Science announced that it expects to receive KRW 6 billion in funding from TiumBio Co., Ltd.	15-09-21
TiumBio Co., Ltd. announced that it has received KRW 49.99982815 billion in funding from Hanyang Securities Co. Ltd., EBEST Investment & Securities Co., Ltd. and other investors	03-09-21
TiumBio Co., Ltd. announced that it has received KRW 25 billion in funding	31-08-21
TiumBio Co., Ltd. announced that it expects to receive KRW 49.99982815 billion in funding from Hanyang Securities Co. Ltd., EBEST Investment & Securities Co., Ltd. and other investors	27-08-21
SK Plasma Co., Ltd. announced that it expects to receive KRW 110.00001 billion in funding from SK Discovery Co., Ltd., TiumBio Co., Ltd., and another investor	28-07-21
TiumBio Co., Ltd.(KOSDAQ:A321550) added to S&P Global BMI Index	22-06-20
TiumBio Co. Ltd. has completed an IPO in the amount of KRW 30 billion.	21-11-19
TiumBio Co. Ltd. has filed an IPO.	24-06-19

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen TiumBio Co., Ltd.

Aandelen

A321550

KR7321550006

Andere talen

Filters